Synthesis of Purine Nucleoside Phosphorylase Inhibitor BCX-4208

V. P. Kamath; J. J. Juarez-Brambila; C. B. Morris; C. D. Winslow Jr.; P. E. Morris

doi:10.1055/s-0029-1219023

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synfacts 2010(2): 0132-0132
DOI: 10.1055/s-0029-1219023

Synthesis of Natural Products and Potential Drugs

Synthesis of Purine Nucleoside Phosphorylase Inhibitor BCX-4208

Contributor(s): Philip Kocienski
V. P. Kamath*, J. J. Juarez-Brambila, C. B. Morris, C. D. Winslow Jr., P. E. Morris
BioCryst Pharmaceuticals, Birmingham, USA

Further Information

Publication History

Publication Date:
21 January 2010 (online)

Permissions and Reprints

Significance

BCX-4208 is an inhibitor of purine nucleoside phosphorylase (PNP). It is currently undergoing clinical trials for the treatment of relapsed/resistant T-cell leukemia. The synthesis depicted in the scheme provided 25 kg batches of the drug.